{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-107471","form_type":"8-K","ticker":"DWTX","cik":"0001818844","company_name":"Dogwood Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.585638+00:00","generated_at":"2026-05-16T23:56:59.535105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dogwood Therapeutics Q3 2025 net loss $15.7M; cash runway through Q1 2026","bullets":["Net loss per share of $8.20 vs. $2.05 in Q3 2024; R&D expenses surged to $14.5M from $0.5M.","100 patients enrolled, 80 completed in Halneuron Phase 2b trial; interim analysis on track for Q4 2025.","Secured exclusive worldwide royalty-free license to develop SP16 for cancer-related pain via all-stock transaction.","Cash and equivalents of $10.1M expected to fund operations into Q1 2026.","SP16 Phase 1b study fully funded by National Cancer Institute; FDA feedback anticipated."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-107471","json":"https://secwatch.observer/filing/0001104659-25-107471.json","markdown":"https://secwatch.observer/filing/0001104659-25-107471.md","text":"https://secwatch.observer/filing/0001104659-25-107471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/0001104659-25-107471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818844/000110465925107471/dwtx-20251106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:56:59.535105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}